Viking VKTX is today's standout, up 25-30%

Summary

Viking Therapeutics (VKTX) rose about 26% following positive weight-loss maintenance study results, according to the hosts. They highlighted reported tolerability, potential dosing flexibility, and earlier unusual options activity that benefited from the stock's rally.

• VKTX climbed about 26%, trading above $41 and roughly $10 above its mid-June lows.
• The hosts attributed the rally to better-than-expected placebo-adjusted weight-loss maintenance results.
• Reported weight loss reached 22% at week 33.
• The hosts emphasized good tolerability as a potential factor supporting continued treatment.
• Less frequent dosing and possible oral maintenance dosing were highlighted.
• Earlier unusual options activity included purchases of 6,000 contracts at the $30 strike.
• With shares above $41, the hosts estimated those options had at least $11 in intrinsic value, compared with an earlier $3 premium.

1. 0:00

   Viking Therapeutics. It's a frequent flyer on our unusual activity reports and on Rebel's Edge. We've talked about this one a lot, VK TX. Well, this one hasn't given back hardly a penny. It just is climbing and climbing and

2. 0:17

   climbing, Pete. It's up 26%.

3. 0:20

   Um and it basically posted positive um maintenance study results. They compared this to a placebo-adjusted weight loss and uh apparently it did much better than expected and that's why

4. 0:35

   you're getting that 26% jump. Shoot, it's up $10 from the middle of June lows, Pete, to today's pop. And you know, the the fact that uh people's guts tolerate this, by that I mean, you know,

5. 0:52

   some people get sick from some of these GLP-1s and things like that. But um this one apparently the tolerability is very good. And so, obviously the the better that is, the better chance people will stay on it and lose their desired amount of weight and all that kind of stuff.

6. 1:10

   This is an unusual activity one, too, Pete. Why don't you tell people about Boy, you missed this one, you missed a lot.

7. 1:17

   >> Yeah, you did. I mean, look >> $32 stock. Now it's in the 40s.

8. 1:21

   >> Yeah, it hit it hit above 41 and change as a matter of fact. And so, here we're looking at these at these 30 strikes, well, those are deep into the money. So, just on on sheer numbers, this is uh at least 11 bucks. So, the $3 to 11 bucks, it's more than that because you've got some time, but I'm just trying to make it as simplistic as we can. So, yeah,

9. 1:40

   this is unusual option activity and there 6,000 of those things were bought and boy, what the timing of this one absolutely extraordinary, John. I mean, just you you can't make it up. But, you know, like you were talking about less frequent dosing, that's something that people are always very happy about. Um

10. 1:59

    oral maintenance dosing is a possibility as well. Some people are not great with, you know, injections and so forth. So, they're they're they've really really covered all the bases. And, you know, weight loss these study results are really really impressive. The loss is 22% in week 33. Uh so, there's a there's a lot of things

11. 2:18

    about this that people are very excited about. Because there's all kind There's competition in this world, of course.

12. 2:24

    And we all know that whether it's uh the the biggest of the big or some of the smaller, there is competition here. But, I think uh what Viking Therapeutic is telling us is, "Hey, they're at the next level." And people are very very happy about what this maintenance really looks like as they're losing weight. And they're not

13. 2:43

    they're not having some of the issues with that weight loss that some of the others are having.

14. 3:04

    >> [music]

Transcript from the show's YouTube captions; automatic captions may contain errors. Educational content, not investment advice.